Cancer powerhouse Roche elbows its way into a checkpoint showdown with Bristol-Myers, Merck
Watch out Bristol-Myers Squibb. Roche is coming for some of your embattled lung cancer business.
The FDA wasted no time in stamping Roche’s up-and-coming PD-L1 checkpoint drug Tecentriq approved for use in the second-line patient group in non-small cell lung cancer. Genentech investigators had nailed down a 4.2-month median improvement in overall survival for the therapy.
The approval sets up a three-way fight for the big lung cancer market, with Merck’s Keytruda now given a solid edge after Bristol-Myers’ Opdivo was routed in a failed attempt to demonstrate efficacy in a broad group of frontline patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
